Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 63Carcinoma, Hepatocellular 55Lung Neoplasms 32Breast Neoplasms 29Small Cell Lung Carcinoma 23Neoplasms 21Triple Negative Breast Neoplasms 18Neoplasm Metastasis 17Urinary Bladder Neoplasms 15Carcinoma, Transitional Cell 15Melanoma 14Colorectal Neoplasms 14Glioblastoma 10Prostatic Neoplasms 9Ovarian Neoplasms 9Head and Neck Neoplasms 9Recurrence 8Liver Neoplasms 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Mesothelioma, Malignant 7Uterine Cervical Neoplasms 6Sarcoma 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Kidney Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Squamous Cell 5Pancreatic Neoplasms 4

Interventions

Gemcitabine 11Cisplatin 11Nivolumab 4Doxorubicin 4pembrolizumab 3avelumab 3Radiotherapy 3Fluorouracil 3Docetaxel 3Carboplatin 3vinflunine 2pegfilgrastim 2Sunitinib 2Platinum 2Paclitaxel 2Immunoglobulin G 2Ifosfamide 2Disulfides 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tremelimumab 1tocilizumab 1temsirolimus 1tamibarotene 1relatlimab 1merphos 1guadecitabine 1enzalutamide 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urethral Neoplasms × atezolizumab × Clear all
NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Fox Chase Cancer Center

Phase 2 Active not recruiting
21 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡